{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:10:32Z","timestamp":1790493032401,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Transmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The <jats:italic>Plasmodium falciparum<\/jats:italic> Pfs25 protein (Pfs25) is the most clinically advanced candidate sexual-stage antigen. IMX313, a complement inhibitor C4b-binding protein that forms heptamers with the antigen fused to it, improve antibody responses. This is the first time that viral vectors have been used to induce antibodies in humans against an antigen that is expressed only in the mosquito vector.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical trial looking at safety and immunogenicity of two recombinant viral vectored vaccines encoding Pfs25-IMX313 in healthy malaria-naive adults. Replication-deficient chimpanzee adenovirus serotype 63 (ChAd63) and the attenuated orthopoxvirus modified vaccinia virus Ankara (MVA), encoding Pfs25-IMX313, were delivered by the intramuscular route in a heterologous prime-boost regimen using an 8-week interval. Safety data and samples for immunogenicity assays were taken at various time-points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The reactogenicity of the vaccines was similar to that seen in previous trials using the same viral vectors encoding other antigens. The vaccines were immunogenic and induced both antibody and T cell responses against Pfs25, but significant transmission reducing activity (TRA) was not observed in most volunteers by standard membrane feeding assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both vaccines were well tolerated and demonstrated a favorable safety profile in malaria-naive adults. However, the transmission reducing activity of the antibodies generated were weak, suggesting the need for an alternative vaccine formulation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p><jats:uri>Clinicaltrials.gov<\/jats:uri> NCT02532049.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.694759","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T13:09:40Z","timestamp":1626268180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Safety and Immunogenicity of ChAd63\/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Hans","family":"de Graaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth O.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iona","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoyo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Zaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Minassian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Silk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Gbesemete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Brendish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mekhaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vekemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Berrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergal","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"B1","unstructured":"World Malaria Report 2019"},{"key":"B2","unstructured":"Action and Investment to Defeat Malaria 2016-2030. For a Malaria-Free World2018"},{"key":"B3","unstructured":"World Malaria Report 20142018"},{"key":"B4","unstructured":"Global Technical Strategy for Malaria 2016-20302018"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0163144","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel(R), a Transmission Blocking Vaccine Against Plasmodium Falciparum: An Open Label Study in Malaria Naive Adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PloS One"},{"key":"B6","unstructured":"Malaria Vaccine Technology Roadmap2018"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1590\/0074-0276130597","article-title":"The Plasmodium Bottleneck: Malaria Parasite Losses in the Mosquito Vector","volume":"109","author":"Smith","year":"2014","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/s41467-017-01924-3","article-title":"Molecular Definition of Multiple Sites of Antibody Inhibition of Malaria Transmission-Blocking Vaccine Antigen Pfs25","volume":"8","author":"Scally","year":"2017","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6766","DOI":"10.1038\/s41598-017-06130-1","article-title":"Evaluation of Two Lead Malaria Transmission Blocking Vaccine Candidate Antibodies in Natural Parasite-Vector Combinations","volume":"7","author":"Bompard","year":"2017","journal-title":"Sci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.15.3975","article-title":"P25 and P28 Proteins of the Malaria Ookinete Surface Have Multiple and Partially Redundant Functions","volume":"20","author":"Tomas","year":"2001","journal-title":"EMBO J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.5.1203","article-title":"Recombinant Pfs25 Protein of Plasmodium Falciparum Elicits Malaria Transmission-Blocking Immunity in Experimental Animals","volume":"174","author":"Barr","year":"1991","journal-title":"J Exp Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/333074a0","article-title":"A Vaccine Candidate From the Sexual Stage of Human Malaria That Contains EGF-Like Domains","volume":"333","author":"Kaslow","year":"1988","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.10.5530-5538.2000","article-title":"A Region of Plasmodium Falciparum Antigen Pfs25 That Is the Target of Highly Potent Transmission-Blocking Antibodies","volume":"68","author":"Stowers","year":"2000","journal-title":"Infect Immun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0609885104","article-title":"Long-Lasting and Transmission-Blocking Activity of Antibodies to Plasmodium Falciparum Elicited in Mice by Protein Conjugates of Pfs25","volume":"104","author":"Kubler-Kielb","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2636","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated With Montanide ISA 51","volume":"3","author":"Wu","year":"2008","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.12.019","article-title":"Phase 1 Vaccine Trial of Pvs25H: A Transmission Blocking Vaccine for Plasmodium Vivax Malaria","volume":"23","author":"Malkin","year":"2005","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.08.033","article-title":"Safety and Immunogenicity of a Plant-Produced Pfs25 Virus-Like Particle as a Transmission Blocking Vaccine Against Malaria: A Phase 1 Dose-Escalation Study in Healthy Adults","volume":"36","author":"Chichester","year":"2018","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120692","article-title":"TLR-Adjuvanted Nanoparticle Vaccines Differentially Influence the Quality and Longevity of Responses to Malaria Antigen Pfs25","volume":"3","author":"Thompson","year":"2018","journal-title":"JCI Insight"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.036","article-title":"The IC(50) of Anti-Pfs25 Antibody in Membrane-Feeding Assay Varies Among Species","volume":"28","author":"Cheru","year":"2010","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01369-07","article-title":"The Oligomerization Domain of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Surface Protein 1 Fused With the Murine C4bp Domain Protects Mice Against Malaria","volume":"76","author":"Ogun","year":"2008","journal-title":"Infect Immun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.01.062","article-title":"A First-in-Human Phase 1 Trial to Evaluate the Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A-IMX313, Administered to BCG-Vaccinated Adults","volume":"34","author":"Minhinnick","year":"2016","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"18848","DOI":"10.1038\/srep18848","article-title":"Enhancing Immunogenicity and Transmission-Blocking Activity of Malaria Vaccines by Fusing Pfs25 to IMX313 Multimerization Technology","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1850","article-title":"Effective Induction of High-Titer Antibodies by Viral Vector Vaccines","volume":"14","author":"Draper","year":"2008","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1586\/erv.13.11","article-title":"Recent Advances in Antibody-Inducing Poxviral and Adenoviral Vectored Vaccine Delivery Platforms for Difficult Disease Targets","volume":"12","author":"de Cassan","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1896-7","article-title":"New Adenovirus-Based Vaccine Vectors Targeting Pfs25 Elicit Antibodies That Inhibit Plasmodium Falciparum Transmission","volume":"16","author":"McGuire","year":"2017","journal-title":"Malaria J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029428","article-title":"A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity","volume":"6","author":"Goodman","year":"2011","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector","volume":"205","author":"O\u2019Hara","year":"2012","journal-title":"J Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e115161","DOI":"10.1371\/journal.pone.0115161","article-title":"A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and With MVA CS","volume":"9","author":"de Barra","year":"2014","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia Clinical Evaluation of the Plasmodium Falciparum Blood-Stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium Falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PloS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-Vectored P. Falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults","volume":"6","author":"Sedegah","year":"2011","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96381","article-title":"Human Vaccination Against RH5 Induces Neutralizing Antimalarial Antibodies That Inhibit RH5 Invasion Complex Interactions","volume":"2","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.83","article-title":"Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1038\/mt.2014.109","article-title":"Translating the Immunogenicity of Prime-Boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-Endemic Populations","volume":"22","author":"Kimani","year":"2014","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93683","article-title":"Human Vaccination Against Plasmodium Vivax Duffy-Binding Protein Induces Strain-Transcending Antibodies","volume":"6","author":"Payne","year":"2017","journal-title":"JCI Insight"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12226","article-title":"Analysis of Human B-Cell Responses Following ChAd63\/MVA MSP1 and AMA1 Immunization and Controlled Malaria Infection","volume":"141","author":"Elias","year":"2014","journal-title":"Immunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057909","article-title":"Qualification of Standard Membrane-Feeding Assay With Plasmodium Falciparum Malaria and Potential Improvements for Future Assays","volume":"8","author":"Miura","year":"2013","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted With MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"300ra126","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee Adenovirus- and MVA-Vectored Respiratory Syncytial Virus Vaccine Is Safe and Immunogenic in Adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"40312","DOI":"10.1038\/srep40312","article-title":"Adjuvant and Carrier Protein-Dependent T-Cell Priming Promotes a Robust Antibody Response Against the Plasmodium Falciparum Pfs25 Vaccine Candidate","volume":"7","author":"Radtke","year":"2017","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e107903","DOI":"10.1371\/journal.pone.0107903","article-title":"Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens Following ChAd63\/MVA Immunization, Controlled Human Malaria Infection and Natural Exposure","volume":"9","author":"Biswas","year":"2014","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2013.10.022","article-title":"Comparison of Field-Based Xenodiagnosis and Direct Membrane Feeding Assays for Evaluating Host Infectiousness to Malaria Vector Anopheles Gambiae","volume":"130","author":"Gouagna","year":"2014","journal-title":"Acta Trop"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1992.47.41","article-title":"Ookinete Rates in Afrotropical Anopheline Mosquitoes as a Measure of Human Malaria Infectiousness","volume":"47","author":"Beier","year":"1992","journal-title":"Am J Trop Med Hyg"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30344-X","article-title":"Safety and Immunogenicity of Pfs25H-EPA\/Alhydrogel, a Transmission-Blocking Vaccine Against Plasmodium Falciparum: A Randomised, Double-Blind, Comparator-Controlled, Dose-Escalation Study in Healthy Malian Adults","volume":"18","author":"Sagara","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e146221","DOI":"10.1101\/2020.11.19.20234922","article-title":"Pfs230 Yields Higher Malaria Transmission-Blocking Vaccine Activity Than Pfs25 in Humans But Not Mice","volume":"131","author":"Healy","year":"2021","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1038\/s41598-017-03798-3","article-title":"Nanoassembly Routes Stimulate Conflicting Antibody Quantity and Quality for Transmission-Blocking Malaria Vaccines","volume":"7","author":"Leneghan","year":"2017","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.7b00174","article-title":"Dual Plug-And-Display Synthetic Assembly Using Orthogonal Reactive Proteins for Twin Antigen Immunization","volume":"28","author":"Brune","year":"2017","journal-title":"Bioconjug Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/s41598-017-01421-z","article-title":"The S. Aureus 4-Oxalocrotonate Tautomerase SAR1376 Enhances Immune Responses When Fused to Several Antigens","volume":"7","author":"Diemen","year":"2017","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.694759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T13:09:49Z","timestamp":1626268189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.694759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2021.694759"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.694759","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"article-number":"694759"}}